Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Chenhe YiLirong ChenZhifei LinLu LiuWeiqing ShaoRui ZhangJing LinJubo ZhangWenwei ZhuHuliang JiaLun-Xiu QinLu LuJin-Hong ChenPublished in: Hepatology (Baltimore, Md.) (2021)
Lenvatinib reduced tumor PD-L1 level and Treg differentiation to improve anti-PD-1 efficacy by blocking FGFR4. Levels of FGFR4 expression and Treg infiltration in tumor could serve as biomarkers for screening patients with HCC using lenvatinib plus anti-PD-1 combination therapy.